Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy

This page covers all Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting VEGF-A (ranibizumab component), COX enzymes (ketorolac); VEGF-A (ranibizumab), VEGF-A.

Targets

VEGF-A (ranibizumab component) · COX enzymes (ketorolac); VEGF-A (ranibizumab) · VEGF-A

Marketed (2)

• Ranibizumab plus Photodynamic therapy · Illinois Retina Associates · Ophthalmology
  Ranibizumab blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth, while photodynamic therapy uses light-activated drugs to destroy diseased retinal tissue.
• Ketorolac + Ranibizumab · Università degli Studi di Brescia · Ophthalmology
  Ketorolac reduces ocular inflammation via COX inhibition while ranibizumab blocks VEGF-A to inhibit pathological neovascularization in the eye.

Phase 3 pipeline (1)

• Brolucizumab Injection [Beovu] · Yeungnam University College of Medicine · Ophthalmology
  Brolucizumab is a single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and leakage in the retina.

Patent intelligence

• vegf monoclonal antibody fragment patent landscape — aggregated cliff calendar, attackable patents, originator estates